Cite
HARVARD Citation
Barlesi, F. et al. (n.d.). 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. Journal for immunotherapy of cancer. p. A178. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Barlesi, F. et al. (n.d.). 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. Journal for immunotherapy of cancer. p. A178. [Online].